A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

"There is more work to be done to understand the mechanism of benefit as the population had a median BMI of 28.6 [kg/m2] and the relationship between the outcome and weight loss was very ...

according to a new study that reinforces the benefits of the popular drug beyond weight loss. The results of the clinical trial, which was co-led by a Canadian doctor, show that semaglutide ...

Liquid Collective is the secure liquid staking standard: a protocol with multi-chain capabilities, built and run by a collective of leading web3 teams. Developed in collaboration with a diverse ...

The STRIDE trial demonstrated that semaglutide significantly improves function, symptoms, and health-related QoL in patients with symptomatic PAD and T2DM. Participants from 112 outpatient sites in 20 ...

The use of semaglutide in patients with diabetes was ... the longitudinal analysis approach may have been subject to potential loss to follow-up and limitations in representativeness.

These compounded versions of the drug, which is marketed by Novo as Wegovy for weight loss and Ozempic for diabetes, could make up as much as 40% of the market, Jorgensen said. He added that Novo has ...